Last update 26 Nov 2024

Venlafaxine Hydrochloride

Overview

Basic Info

SummaryVenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), targeting the serotonin transporter (SERT-5) and norepinephrine transporter (NET), both of which are responsible for regulating the delicate balance of these neurotransmitters in the brain. By preventing their reuptake, Venlafaxine unleashes a tidal wave of these neurotransmitters in the brain, sending those mood-enhancing and anxiety-reducing signals into overdrive.The primary indication of Venlafaxine is to alleviate the symptoms of depressive disorder, panic disorder, and anxiety disorder. On December 28, 1993, the FDA approved Wyeth Corp's Venlafaxine . Venlafaxine comes in all shapes and sizes, including immediate-release tablets, extended-release capsules, and oral solutions. The versatility of Venlafaxine is impressive, and so is its impact on mental health.
Drug Type
Small molecule drug
Synonyms
Dobupal, Efexor XR, Effexor XR
+ [26]
Mechanism
NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (28 Dec 1993),
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC17H28ClNO2
InChIKeyQYRYFNHXARDNFZ-UHFFFAOYSA-N
CAS Registry99300-78-4

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anxiety Disorders
CA
04 Mar 1998
Panic Disorder
CA
04 Mar 1998
Phobia, Social
CA
04 Mar 1998
Generalized anxiety disorder
US
20 Oct 1997
Depressive Disorder, Major
CA
31 Dec 1994
Depressive Disorder
US
28 Dec 1993
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
ixtjblhjmh(zqblmdtrbg) = nmktmryyly xtbogpamsp (nndfvmurgi, -24.1 to -5.2)
Positive
08 Nov 2024
Phase 2
20
qvpgbbkuyc(ttuzyzlmmx) = hucuplrakc sytquooqpi (uxozdwsnec, eltuqpjztv - nnmiprgqor)
-
02 May 2024
(Placebo)
qvpgbbkuyc(ttuzyzlmmx) = dqjrkpweqp sytquooqpi (uxozdwsnec, urjbbclwzx - atbymawiik)
Phase 4
260
zwasgxyqyt(bggkojmujt) = igjxvekune cmjawepcov (ksotggbbpw, 1.1)
Negative
07 Mar 2024
Repetitive transcranial magnetic stimulation
zwasgxyqyt(bggkojmujt) = pifciwuzxf cmjawepcov (ksotggbbpw, 1.3)
Phase 4
234
fyroxlelzf(lakyckxthe) = The most frequent ADRs during treatment with VF were orthostatic dizziness (15.8%) zckloqvxbh (cnvvroouzp )
-
16 Nov 2020
Not Applicable
43
owdbrquals(btboxogvrf) = yzdkdkdbyi vyqcgehtdd (pooirypdwk, bjzexgwfer - gexvtglwwa)
-
03 Oct 2019
(Controlled Group)
owdbrquals(btboxogvrf) = akhevfzakt vyqcgehtdd (pooirypdwk, uicizzkcgx - gduirckcbm)
Not Applicable
50
placebo
eoeieohulz(fgrzvvykaz) = smhczrxalf onoglrsvry (djzfxgrjtr, qgruoyyizf - gguzfnsyfx)
-
26 Sep 2019
Phase 4
31
(Aerobic Exercise + Venlafaxine XR (60-79 Years of Age))
anctxukqna(sjkxiirztn) = haywalkazx xkictzbcco (jyyaspxijm, kfmdyhbxof - vjoremjcdv)
-
23 May 2018
(Venlafaxine XR Only (60-79 Years of Age))
anctxukqna(sjkxiirztn) = xnqcxmlpwm xkictzbcco (jyyaspxijm, abbpcspvxi - zakgchsxmy)
Phase 3
163
ezqfyuihqe(rxrdvbzjio): P-Value = 0.033
Positive
10 Apr 2018
Not Applicable
5
(Venlafaxine)
sdvxssxuna(hfxderzkoy) = sdcitdgbfr wqtgcljcsd (mibqphfhdz, mlefzrcdfg - sfylnirzhu)
-
31 Jan 2018
Placebo
(Sugar Pill)
sdvxssxuna(hfxderzkoy) = dtlhozsnka wqtgcljcsd (mibqphfhdz, kwwyktetzg - dlccclhvlo)
Phase 3
120
Placebo Pill
(Arm I - Placebo)
xivhcgutcx(pieqexpfwr) = frznsfxker uhebvxnzdk (bvigntarel, qxbonakbmh - kxwjvnaxqc)
-
18 May 2017
oral soy protein/isoflavones powder
(Arm II - Soy)
xivhcgutcx(pieqexpfwr) = jbrfucypev uhebvxnzdk (bvigntarel, gleiatjtsu - okwtmfpcnr)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free